Associated Papers
Insights Into Genetic Variations of the OCT1 Gene in Metformin Poor Responders Among Bangladeshi Type 2 Diabetic Patients.
Begum R et al.
Advances in Pharmacological and Pharmaceutical Sciences, 2025
The full spectrum of SLC22 OCT1 mutations illuminates the bridge between drug transporter biophysics and pharmacogenomics.
Yee SW et al.
Molecular Cell, 2024
The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics.
Yee SW et al.
Biorxiv : the Preprint Server for Biology, 2023
Genetic Variant ABCC1 rs45511401 Is Associated with Increased Response to Statins in Patients with Familial Hypercholesterolemia.
Dagli-Hernandez C et al.
Pharmaceutics, 2022
The Impact of Genetic Polymorphisms in Organic Cation Transporters on Renal Drug Disposition.
Zazuli Z et al.
International Journal of Molecular Sciences, 2020
Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma.
Alonso-Peña M et al.
Cancer Drug Resistance (alhambra, Calif.), 2019
Recent advance in the pharmacogenomics of human Solute Carrier Transporters (SLCs) in drug disposition.
Zhou F et al.
Advanced Drug Delivery Reviews, 2017
Characterization of ADME gene variation in 21 populations by exome sequencing.
Hovelson DH et al.
Pharmacogenetics and Genomics, 2017
Characterization of Disease-Associated Mutations in Human Transmembrane Proteins.
Molnár J et al.
Plos One, 2016
Genetic polymorphisms of the organic cation transporter 1 gene (SLC22A1) within the Cape Admixed population of South Africa.
Du Plessis M et al.
Molecular Biology Reports, 2015
Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1.
Seitz T et al.
Genome Medicine, 2015
Genetic polymorphisms and haplotypes of the organic cation transporter 1 gene (SLC22A1) in the Xhosa population of South Africa.
Jacobs C et al.
Genetics and Molecular Biology, 2014
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Herraez E et al.
Hepatology (baltimore, Md.), 2013
Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology.
Lozano E et al.
Biomed Research International, 2013
Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.
Mannino GC et al.
Molecular Diagnosis & Therapy, 2012
Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
Lai Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Transporter pharmacogenetics: transporter polymorphisms affect normal physiology, diseases, and pharmacotherapy.
Sissung TM et al.
Discovery Medicine, 2012
Screening of genetic variations of SLC15A2, SLC22A1, SLC22A2 and SLC22A6 genes.
Cheong HS et al.
Journal of Human Genetics, 2011
OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.
White DL et al.
Leukemia, 2010
Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function.
Chen L et al.
The Journal of Pharmacology and Experimental Therapeutics, 2010
Genetic variation in metabolizing enzyme and transporter genes: comprehensive assessment in 3 major East Asian subpopulations with comparison to Caucasians and Africans.
Man M et al.
Journal of Clinical Pharmacology, 2010
Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver.
Nies AT et al.
Hepatology (baltimore, Md.), 2009
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine.
Avery P et al.
Pharmacogenomics and Personalized Medicine, 2009
Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions.
Sakata T et al.
Biochemical and Biophysical Research Communications, 2004
Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1.
Shu Y et al.
Proceedings of the National Academy of Sciences of the United States of America, 2003